Literature DB >> 16896942

Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models.

I G Obrosova1, V R Drel, A K Kumagai, C Szábo, P Pacher, M J Stevens.   

Abstract

AIMS/HYPOTHESIS: Recently, various transgenic and knock-out mouse models have become available for studying the pathogenesis of diabetic retinopathy. At the same time, diabetes-induced retinal changes in the wild-type mice remain poorly characterised. The present study compared retinal biochemical changes in rats and mice with similar (6-week) durations of streptozotocin-induced diabetes.
MATERIALS AND METHODS: The experiments were performed on Wistar rats and C57Bl6/J mice. Retinal glucose, sorbitol, fructose, lactate, pyruvate, glutamate, alpha-ketoglutarate and ammonia were measured spectrofluorometrically by enzymatic methods. Vascular endothelial growth factor (VEGF) protein was assessed by ELISA, and poly(ADP-ribosyl)ation by immunohistochemistry and western blot analysis. Free mitochondrial and cytosolic NAD(+)/NADH ratios were calculated from the glutamate and lactate dehydrogenase systems.
RESULTS: Retinal glucose concentrations were similarly increased in diabetic rats and mice, vs controls. Diabetic rats manifested approximately 26- and 5-fold accumulation of retinal sorbitol and fructose, respectively, whereas elevation of both metabolites in diabetic mice was quite modest. Correspondingly, diabetic rats had (1) increased retinal malondialdehyde plus 4-hydroxyalkenal concentrations, (2) reduced superoxide dismutase (SOD), glutathione peroxidase, glutathione reductase and glutathione transferase activities, (3) slightly increased poly(ADP-ribose) immunoreactivity and poly(ADP-ribosyl)ated protein abundance, and (4) VEGF protein overexpression. Diabetic mice lacked these changes. SOD activity was 21-fold higher in murine than in rat retinas (the difference increased to 54-fold under diabetic conditions), whereas other antioxidative enzyme activities were 3- to 10-fold lower. With the exception of catalase, the key antioxidant defence enzyme activities were increased, rather than reduced, in diabetic mice. Diabetic rats had decreased free mitochondrial and cytosolic NAD(+)/NADH ratios, consistent with retinal hypoxia, whereas both ratios remained in the normal range in diabetic mice. CONCLUSIONS/
INTERPRETATION: Mice with short-term streptozotocin-induced diabetes lack many biochemical changes that are clearly manifest in the retina of streptozotocin-diabetic rats. This should be considered when selecting animal models for studying early retinal pathology associated with diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896942      PMCID: PMC2228251          DOI: 10.1007/s00125-006-0356-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid.

Authors:  I G Obrosova; L Fathallah; D A Greene
Journal:  Eur J Pharmacol       Date:  2000-06-09       Impact factor: 4.432

2.  Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy.

Authors:  R A Kowluru; J Tang; T S Kern
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

3.  A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy.

Authors:  T Purves; A Middlemas; S Agthong; E B Jude; A J Boulton; P Fernyhough; D R Tomlinson
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

4.  Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat.

Authors:  E Ann Ellis; Dennis L Guberski; Brenda Hutson; Maria B Grant
Journal:  Nitric Oxide       Date:  2002-05       Impact factor: 4.427

5.  Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats.

Authors:  I G Obrosova; A G Minchenko; V Marinescu; L Fathallah; A Kennedy; C M Stockert; R N Frank; M J Stevens
Journal:  Diabetologia       Date:  2001-09       Impact factor: 10.122

6.  Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia.

Authors:  T S Kern; J Tang; M Mizutani; R A Kowluru; R H Nagaraj; G Romeo; F Podesta; M Lorenzi
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-11       Impact factor: 4.799

7.  Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes.

Authors:  Rachel A Feit-Leichman; Reiko Kinouchi; Masumi Takeda; Zhigang Fan; Susanne Mohr; Timothy S Kern; Dong Feng Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-11       Impact factor: 4.799

8.  Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes.

Authors:  J W Cruz; M A Oliveira; T C Hohman; Z B Fortes
Journal:  Eur J Pharmacol       Date:  2000-03-10       Impact factor: 4.432

9.  A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications.

Authors:  Jithan V Aukunuru; Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Randall C Clark; Uday B Kompella
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

10.  Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy.

Authors:  I G Obrosova; M J Stevens; H J Lang
Journal:  Pharmacology       Date:  2001       Impact factor: 2.547

View more
  37 in total

1.  Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina.

Authors:  Q Wang; F Pfister; A Dorn-Beineke; F vom Hagen; J Lin; Y Feng; H P Hammes
Journal:  Diabetologia       Date:  2010-03-26       Impact factor: 10.122

2.  Catalase therapy corrects oxidative stress-induced pathophysiology in incipient diabetic retinopathy.

Authors:  Courtney R Giordano; Robin Roberts; Kendra A Krentz; David Bissig; Deepa Talreja; Ashok Kumar; Stanley R Terlecky; Bruce A Berkowitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

3.  Diabetic eNOS-knockout mice develop accelerated retinopathy.

Authors:  Qiuhong Li; Amrisha Verma; Ping-Yang Han; Takahiko Nakagawa; Richard J Johnson; Maria B Grant; Martha Campbell-Thompson; Yagna P R Jarajapu; Bo Lei; William W Hauswirth
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-30       Impact factor: 4.799

4.  Prorenin receptor (PRR)-mediated NADPH oxidase (Nox) signaling regulates VEGF synthesis under hyperglycemic condition in ARPE-19 cells.

Authors:  Rashidul Haque; P Michael Iuvone; Li He; Elizabeth H Hur; Kimberly Su Chung Choi; Daniel Park; Annie N Farrell; Ashley Ngo; Samantha Gokhale; Madiha Aseem; Bhavna Kumar
Journal:  J Recept Signal Transduct Res       Date:  2017-08-25       Impact factor: 2.092

Review 5.  Spermine oxidase: A promising therapeutic target for neurodegeneration in diabetic retinopathy.

Authors:  S Priya Narayanan; Esraa Shosha; Chithra D Palani
Journal:  Pharmacol Res       Date:  2019-06-15       Impact factor: 7.658

Review 6.  Nutrient excess and altered mitochondrial proteome and function contribute to neurodegeneration in diabetes.

Authors:  Subir K Roy Chowdhury; Rick T Dobrowsky; Paul Fernyhough
Journal:  Mitochondrion       Date:  2011-07-02       Impact factor: 4.160

Review 7.  Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events.

Authors:  Paul Fernyhough
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

8.  Effect of stem cell therapy on induced diabetic keratopathy in albino rat.

Authors:  Maha Baligh Zickri; Nagwa Abdel Wahab Ahmad; Zeinab Mohamad El Maadawi; Yasmin Kamal Mohamady; Hala Gabr Metwally
Journal:  Int J Stem Cells       Date:  2012-05       Impact factor: 2.500

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

10.  Epac1 is upregulated during neointima formation and promotes vascular smooth muscle cell migration.

Authors:  Utako Yokoyama; Susumu Minamisawa; Hong Quan; Toru Akaike; Meihua Jin; Koji Otsu; Coskun Ulucan; Xu Wang; Erdenechimeg Baljinnyam; Minoru Takaoka; Masataka Sata; Yoshihiro Ishikawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.